Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.30 USD
Change Today +0.098 / 49.00%
Volume 2.3M
IMUN On Other Exchanges
Symbol
Exchange
OTC US
OTC US
As of 8:10 PM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

immune therapeutics inc (IMUN) Snapshot

Open
$0.20
Previous Close
$0.20
Day High
$0.30
Day Low
$0.18
52 Week High
08/4/14 - $0.37
52 Week Low
06/23/15 - $0.05
Market Cap
43.1M
Average Volume 10 Days
551.3K
EPS TTM
--
Shares Outstanding
144.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IMMUNE THERAPEUTICS INC (IMUN)

Related News

No related news articles were found.

immune therapeutics inc (IMUN) Related Businessweek News

No Related Businessweek News Found

immune therapeutics inc (IMUN) Details

Immune Therapeutics, Inc. focuses on the development and commercialization of therapeutic treatments for cancer, HIV/AIDS and autoimmune diseases, and immune disorders in the United States. The company develops IRT-101, an active immunotherapy systemic administration of methionine-enkephalin that works by stimulating and/or regulating a patient’s immune system against infectious diseases, autoimmune diseases, immune disorders, and tumor cells. It also develops IRT-103, an immunotherapy for the treatment of various autoimmune diseases or immune disorders, such as Crohn's disease and multiple sclerosis; HIV/AIDS; and chemotherapy, radiation treatment, or surgery. The company was formerly known as TNI BioTech, Inc. and changed its name to Immune Therapeutics, Inc. in December 2014. Immune Therapeutics, Inc. is headquartered in Orlando, Florida.

6 Employees
Last Reported Date: 03/31/15

immune therapeutics inc (IMUN) Top Compensated Officers

Founder, Chairman and Chief Executive Officer
Total Annual Compensation: $364.6K
Chief Financial Officer
Total Annual Compensation: $60.0K
Chief Medical Officer, Director of Research &...
Total Annual Compensation: $50.0K
Chief Science Officer
Total Annual Compensation: $30.0K
Compensation as of Fiscal Year 2014.

immune therapeutics inc (IMUN) Key Developments

Immune Therapeutics, Inc. Announces Executive Changes

On June 16, 2015, The board of directors removed Mr. Seth Elliott from his positions of President and Chief Operating Officer of Immune Therapeutics, Inc., removed Mr. Vincent Butta as a member of board of directors, and in connection with such removals, approved the termination of the Consulting Agreement between The Sevin Group, LLC and us, effective December 17, 2014.

Immune Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt

Immune Therapeutics, Inc. filed its 10-K on Mar 31, 2015 for the period ending Dec 31, 2014. In this report its auditor, Turner, Stone & Company, LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc

Immune Therapeutics, Inc. announced the signing of the agreement with KRS Global Biotechnology, Inc. for the compounding, packaging and distributing of its naltrexone tablets. The tablets will be compounded for shipment in the United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMUN:US $0.30 USD +0.098

IMUN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IMUN.
View Industry Companies
 

Industry Analysis

IMUN

Industry Average

Valuation IMUN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13,410.1x
Price/Book 23.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 13,228.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNE THERAPEUTICS INC, please visit www.immunetherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.